CN219810955U - Saliva insulin level's short-term test structure - Google Patents
Saliva insulin level's short-term test structure Download PDFInfo
- Publication number
- CN219810955U CN219810955U CN202321130177.4U CN202321130177U CN219810955U CN 219810955 U CN219810955 U CN 219810955U CN 202321130177 U CN202321130177 U CN 202321130177U CN 219810955 U CN219810955 U CN 219810955U
- Authority
- CN
- China
- Prior art keywords
- detection
- saliva
- reagent strip
- sample
- rapid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003296 saliva Anatomy 0.000 title claims abstract description 135
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 109
- 229940125396 insulin Drugs 0.000 title claims abstract description 64
- 108090001061 Insulin Proteins 0.000 title claims abstract description 45
- 102000004877 Insulin Human genes 0.000 title claims abstract description 45
- 238000012031 short term test Methods 0.000 title description 2
- 238000001514 detection method Methods 0.000 claims abstract description 220
- 238000005070 sampling Methods 0.000 claims abstract description 73
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 55
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 20
- 239000012528 membrane Substances 0.000 claims description 38
- 239000000020 Nitrocellulose Substances 0.000 claims description 30
- 229920001220 nitrocellulos Polymers 0.000 claims description 30
- 239000004005 microsphere Substances 0.000 claims description 27
- 239000004816 latex Substances 0.000 claims description 21
- 229920000126 latex Polymers 0.000 claims description 21
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 238000003018 immunoassay Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 239000010902 straw Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 238000007789 sealing Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108010057186 Insulin Glargine Proteins 0.000 description 7
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229960002869 insulin glargine Drugs 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007649 pad printing Methods 0.000 description 2
- 238000012123 point-of-care testing Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model discloses a rapid detection structure of saliva insulin level, which is a combined set of a saliva sampling structure, a saliva sample transferring structure and a chromatography detection structure, wherein the saliva sampling structure is a container-like structure with an upward opening, the chromatography detection structure comprises a detection reagent strip, a detection shell for placing the detection reagent strip and a detection reagent strip bracket arranged on the detection shell, the detection reagent strip is coated with a first anti-insulin antibody marked by an indicator and a non-marked second anti-insulin antibody, the saliva sample transferring structure is a pipette structure, and the rapid detection structure is suitable for the determination of the insulin level of saliva samples, improves the detection efficiency, convenience and accuracy and has important clinical significance.
Description
Technical Field
The utility model relates to the technical field of medical appliances, in particular to a rapid saliva insulin level detection structure.
Background
Insulin is a protein hormone secreted by islet beta cells in the pancreas, consisting of two peptide chains, a and B, regulated by endogenous or exogenous substances such as glucose, lactose, ribose, arginine, glucagon, and the like. Insulin is the most important protein hormone for promoting anabolism of human body, and can promote glucose uptake and utilization by tissue cells, promote glycogen synthesis, inhibit gluconeogenesis and reduce blood sugar; the composition can promote fatty acid synthesis and fat storage, and reduce fat decomposition; amino acids can be promoted to enter cells for proteins, and various links of protein synthesis can be promoted to increase protein synthesis. The immunological detection technology is a saliva insulin level detection method commonly used at present, and comprises an immunonephelometry method, a chemiluminescence method, an enzyme-linked immunosorbent assay method, a chemiluminescence immunoassay method, a time-resolved immunofluorescence method, a quantum dot immunofluorescence chromatography method, a latex immunonephelometry method, a latex enhanced immunonephelometry method, a fluorescence immunochromatography method and the like. High sensitivity, rapidness, convenience, miniaturization, full quantification, automation and household are the development trend of the current clinical immunodetection technology. Point of care testing (POCT) is one of the fastest growing branches of the current immunological testing technology, and chromatographic immunodetection is the most commonly used testing method, wherein colloidal gold chromatography, fluorescence chromatography and color latex microsphere chromatography are the most widely used products, and the used testing samples include blood, urine, saliva, sputum, sweat, swab mucus and the like. Blood is most commonly used compared to other samples, but is less accepted than other samples because its sampling pattern is invasive. At present, clinical detection of insulin level adopts blood samples, and interpretation from sampling and detection results is still limited to operation and use of a laboratory and professionals, so that the clinical detection of insulin level cannot be popularized and used to families and medical institutions lacking corresponding detection conditions. However, studies of salivary insulin levels have been largely reported and have a clear correlation with blood insulin levels. A large number of researches prove that the insulin is a protein hormone and important regulation indexes and markers for directly influencing various metabolic related diseases and bad health states including diabetes, and is suitable for detecting various diseases and health states in and out of hospitals, so that the insulin can be developed for detecting and using medical institutions with home self-tests and lack of corresponding detection conditions, has a saliva insulin level rapid detection technology which is simple and convenient to operate, rapid to use and low in cost, is beneficial to improving medical quality and efficiency, and has important clinical significance and application value.
Disclosure of Invention
The utility model aims to provide a rapid detection structure for saliva insulin level, which has the advantages of convenient and rapid detection operation, low cost and the like compared with the prior art, and improves the detection quality.
In view of the above, the present utility model provides a rapid saliva insulin level detection structure, which is characterized in that:
1) The rapid detection structure is a combined detection structure of a saliva sampling structure, a saliva sample moving structure and a chromatography detection structure;
2) The chromatographic detection structure comprises a detection reagent strip, a detection shell upper cover and a detection shell base, a sample adding hole and an observation window which are arranged on the detection shell upper cover, and a detection reagent strip bracket arranged on the detection shell base, wherein the detection shell upper cover and the detection shell base are used for placing the detection reagent strip;
3) The detection reagent strip comprises a sample pad, a marker binding pad, a nitrocellulose membrane and a water absorption pad, wherein the marker binding pad is coated with a first anti-insulin antibody marked by an indicator, and the nitrocellulose membrane is coated with a second non-marked anti-insulin antibody;
4) The saliva sampling structure is a container-like structure with an upward opening and comprises a cup shape or a tubular shape;
5) The saliva sample transferring structure is a liquid transferring straw structure and comprises a liquid transferring straw with a sealed top end or a liquid transferring straw with an opened top end.
The detection reagent strip is a sample pad, a marker binding pad, a nitrocellulose membrane and a water absorption pad which are sequentially stuck on the PVC bottom sheet, and is placed in a detection shell, and the detection shell is of a rigid structure or a flexible structure.
In the rapid detection structure, the saliva sampling structure is a cup-shaped structure provided with a handle.
In the rapid detection structure, the saliva sampling structure is a container-like structure with a folding opening upwards, the bottom is sealed, and the opening can be opened to be a container structure by pressurizing at two sides.
In the rapid detection structure, the saliva sampling structure is a detachable structure provided with a funnel-like sampling structure and a container-like collecting structure.
In the rapid detection structure, the detection reagent strip is at least one of a colloidal gold immunoassay reagent strip, a fluorescent immunoassay reagent strip and a color latex microsphere immunoassay reagent strip, and the indicator is at least one of colloidal gold particles, color latex microspheres and fluorescent substances.
In the rapid detection structure, the rapid detection structure is provided with a semi-quantitative color chart with the same color as the indicator, and 3 or more color strips with different color depths are printed on the color chart.
In the above-mentioned rapid detection structure, the rapid detection structure is configured with a portable quantitative detector including at least one of a colorimetric quantitative analyzer and a fluorescent quantitative analyzer.
In the above-mentioned rapid detection structure, the operation of the rapid detection structure includes the following steps:
1) Taking out the chromatographic detection structure, the saliva sample moving structure and the saliva sampling structure;
2) The saliva sampling structure is held by hand, and saliva is collected into the sampling container structure;
3) Taking out the saliva sample transferring structure, sucking a proper amount of saliva sample, and dripping the saliva sample into a sample adding hole of the chromatographic detection structure;
4) The saliva sample passes through the sample pad and forwards flows through the marker binding pad, the nitrocellulose membrane and the water absorption pad;
5) And reading the detection result from the observation window to finish detection.
Due to the adoption of the technical scheme, the utility model has the following advantages:
1. the utility model relates to a rapid detection structure of saliva insulin level, which comprises a saliva sampling structure, a saliva sample transferring structure and a detachable combined structure of a chromatography detection structure, can detect human insulin level by saliva without taking an interventional blood sample, is convenient to detect and high in acceptability, and can obviously improve timeliness of clinical detection and feasibility of popularization and promotion and improve clinical diagnosis and treatment effects.
2. The saliva sampling structure is a cup-shaped structure provided with the handle, so that saliva samples can be collected by being directly placed at the oral cavity part in a handheld manner, and can be directly used for detection by the sample moving structure, so that quantitative or semi-quantitative operation is feasible and convenient to operate, and the convenience and the quick operability of technical products are realized.
3. The saliva sampling structure is a container-like structure with an upward folding opening, the bottom is sealed, the folding structure can open the opening to form the container structure by pressing the two sides, the opening can be opened by pressing the two sides directly by hand, saliva samples can be collected at the oral cavity part and can be directly used for detection by the sample moving structure, so that quantitative or semi-quantitative operation is feasible and convenient, meanwhile, the folding structure is convenient to store and transport, and the convenience and the quick operability of technical products are realized.
4. The saliva sampling structure is a detachable structure provided with the funnel-shaped sampling cup and the container-shaped structure, and the funnel-shaped sampling cup and the container-shaped structure are arranged separately and are connected together when in use, so that the saliva sampling structure is convenient to store and transport, is beneficial to independent storage of samples, avoids pollution, and is convenient to detect and improves the detection accuracy.
5. The colorimetric card for semi-quantitatively detecting the color intensity of the detection strip is arranged, the semi-quantitatively judging of the detection result can be carried out through the comparison of the colorimetric card, the method is suitable for clinical application scenes without accurate quantification and only by observing the variation trend of the saliva insulin level, and the clinical application value is improved.
6. The utility model has simple operation steps, is easy to realize household use or self detection, is convenient to use, reduces the waste of raw materials, simultaneously obviously improves the working efficiency, and can be applied to various fields of professional and amateur detection.
Drawings
FIG. 1 is a schematic diagram of the overall structure of the present utility model;
FIG. 2 is a schematic diagram of the structure of a test strip according to the present utility model;
FIG. 3 is a schematic view of a detachable combination structure according to the present utility model;
FIG. 4 is a schematic view of a cup-shaped saliva sampling structure provided with a handle according to the present utility model;
FIG. 5 is a schematic view of a folded-open-top container-like saliva sampling structure of the present utility model;
FIG. 6 is a schematic diagram of a removable combination of a funnel-like saliva sampling structure and a container-like structure according to the present utility model;
FIG. 7 is a schematic diagram of a semi-quantitative colorimetric structure of the present utility model.
The figures are labeled as follows:
saliva sampling structure 1; saliva sample transfer structure 2; a chromatography detection structure 3; a sampling structure opening 4; a sample moving structure handle 5; a sample moving structure dripper 6; a detection housing base 7; a sample addition hole 8; an observation window 9; a test strip 10; a detection housing upper cover 11; a sample pad 12; a label binding pad 13; a nitrocellulose membrane pad 14; a water absorbing pad 15; a PVC support backsheet 16; a detection line 17; a quality control line 18; a saliva sample 19; a sampling handle structure 20; a container sidewall 21; a container bottom 22; a container opening 23; a sampling structure handle 24; a foldable cone-shaped container body 25; a collapsible container fold line 26; an upper opening 27 of the collapsible cone-shaped container; a collapsible cone container storage state 28; a use state 29; sealing the bottom 30; a funnel upper opening 31; saliva sampling structure 32; a funnel lower mouth 33; a saliva collecting tube cover 34; a saliva collection structure 35; semi-quantitative color chart 36.
Description of the embodiments
In order to further illustrate the technical means and effects adopted by the present utility model to achieve the preset purpose, the following embodiments are used for further illustrating the present utility model with reference to the accompanying drawings, but the present utility model is not limited to the following description.
As shown in fig. 1, the whole structure of the utility model comprises a saliva sampling structure 1, a saliva sample moving structure 2 and a chromatography detection structure 3; the saliva sampling structure 1 is a container-like structure with an upward opening and consists of a container side wall, a container bottom and a sampling structure opening 4; the saliva sample moving structure 2 is a suction tube sample structure and consists of a sample moving structure handle 5, a sample moving structure body part and a sample moving structure dripper 6; the chromatography detection structure 3 is a detection buckle card and consists of a detection shell base 7, a detection shell upper cover 11 and a detection reagent strip 10 placed on the base, wherein a sample adding hole 8 for detecting sample adding and an observation window 9 for observing detection results are arranged on the detection shell upper cover 11.
As shown in fig. 2 and 3, the detection reagent strip of the present utility model comprises a sample pad 12, a label binding pad 13, a nitrocellulose membrane pad 14 and a water absorbing pad 15, which are sequentially arranged on a PVC support backsheet 16, wherein a first anti-insulin antibody marked by an indicator is sprayed on the label binding pad 10 as a detection indicator, the indicator is usually colloidal gold particles, color latex microspheres and fluorescent microspheres, a second non-labeled anti-insulin antibody is coated on the nitrocellulose membrane pad 14 as a detection line 17, and a non-labeled non-insulin specific binding antibody, such as goat anti-mouse IgG, is coated on the nitrocellulose membrane pad as a quality control line 18. When the saliva sample 19 is used, firstly, a saliva sample 19 is collected by the saliva sampling structure 1, a proper amount of saliva sample 19 is sucked by the saliva sample transferring structure 2, the collected saliva sample 19 is loaded on the sample pad 12 of the detection reagent strip 10 through the sample loading hole 8, the sample passes through the marker binding pad 13, insulin in the sample is combined with the first insulin resistant antibody marked by the indicator to form a first compound of the first insulin resistant antibody marked by the indicator combined with the insulin, the sample passes through the nitrocellulose membrane pad 14 and is captured by the non-marked second insulin resistant antibody coated on the nitrocellulose membrane pad 14 to form a second compound of the first insulin resistant antibody marked by the indicator combined with the insulin and the second insulin resistant antibody, the second compound is fixedly accumulated on the nitrocellulose membrane pad 14 and developed to form a developed or fluorescent developed detection line 17, the detection result is observed through the observation window 9, the development depth of the detection result is in proportion to the insulin content in the sample, and further the saliva insulin level detection is completed.
As shown in fig. 3 and 4, the saliva sampling structure of the rapid test structure of the present utility model is a cup-shaped structure with a handle, which is an upwardly open container-like structure, and comprises a container sidewall 21, a container bottom 22, an upwardly open container 23, and a sampling structure handle 24 connected to the sidewall. In use, the sampling structure handle 24 is held by hand, the container opening 23 is placed at the saliva sample collecting position, the saliva sample 19 is directly collected, the collected saliva sample 19 is further loaded onto the detection reagent strip 10 positioned in the chromatographic detection structure 3, the detection reaction is started, and the detection process is completed.
As shown in fig. 3 and 5, the saliva sampling structure of the rapid detection structure of the utility model is a container-like structure with a folding opening upwards, the bottom is sealed, and the folding structure can enable the opening to be opened to form a container structure when two sides are pressed oppositely, and the container structure comprises a cone shape and a column shape. The foldable cone-shaped saliva sampling structure includes a foldable cone-shaped container body 25, foldable container folding lines 26 located at both sides of the container body, and an upper opening 27 of the foldable cone-shaped container. The collapsible cone-shaped container has two states, a storage state 28 and a use state 29; in the storage state 28, the upper opening 27 is closed; in the use state 29, the upper opening 27 is in an open state. The collapsible cone-shaped container-like structure is provided with a sealing bottom 30. When in use, the foldable cone-shaped saliva sampling structure in the storage state 28 is taken, the foldable cone-shaped sampling structure is pressed at two sides, so that the upper opening of the foldable container-like structure is opened, namely, the saliva sample 19 can be directly collected in the use state 29, the collected saliva sample 19 is further loaded onto the detection reagent strip 10 in the chromatographic detection structure 3, the detection reaction is started, and the detection process is completed.
As shown in fig. 3 and 6, the saliva sampling structure of the rapid detection structure of the present utility model is a detachable structure provided with a funnel-like sampling structure and a container-like collecting structure, and comprises a saliva sampling structure 32 and a saliva collecting structure 35, wherein the saliva sampling structure 32 is a funnel-like structure, and is connected with the saliva collecting structure 35 in a detachable manner, and the saliva collecting structure 35 is a tubular structure, comprising a funnel upper opening 31 and a funnel lower opening 33. A saliva collecting tube cover 34 is provided in addition to the saliva collecting structure 35. The saliva sampling structure 32 may be selected from a generally fixed funnel shape or a foldable open-and-close funnel shape. In operation, saliva sample 19 is collected by saliva sampling structure 32 and collected into saliva collecting structure 35, and further the collected saliva sample 19 is applied to test reagent strip 10 in chromatographic test structure 3, and the test reaction is initiated and the test process is completed.
As shown in FIG. 7, the semi-quantitative color chart is prepared by adopting saliva samples to prepare insulin solutions with different concentrations, directly dripping the insulin solutions with different concentrations into a sample adding window of a chromatographic detection structure, observing the color depth of a detection line, photographing, designing and printing the semi-quantitative color chart with corresponding concentrations according to photographing results, and taking the semi-quantitative color chart as a comparison basis for interpretation of the follow-up saliva sample semi-quantitative detection results. Examples are as follows: in use, 1, 5, 10, 15, 20, 25, 30 uIU/ml of insulin solution is prepared using fresh saliva. Taking insulin solutions with different concentrations, directly dripping the insulin solutions into a sample adding window of a chromatographic detection structure, standing, observing the color depth of a detection line, photographing, designing and printing a semi-quantitative color comparison card 36 according to photographing results, and taking the semi-quantitative color comparison card as a comparison basis for interpretation of the follow-up saliva sample semi-quantitative detection results.
In practical operation, when the rapid detection structure is a colloidal gold immune detection structure, the detection reagent strip is prepared by a colloidal gold method, and a sample pad, a colloidal gold binding pad coated with a colloidal gold-labeled first anti-insulin antibody, a nitrocellulose membrane pad coated with a non-labeled second anti-insulin antibody and a water absorption pad are sequentially adhered on a PVC negative film; when the rapid detection structure is a color latex microsphere immune detection structure, the detection reagent strip is prepared by a color latex microsphere immune method, and a sample pad, a latex color latex microsphere combination pad coated with a color latex microsphere marker, a nitrocellulose membrane pad coated with a non-marked capture reagent and a water absorption pad are sequentially stuck on a PVC negative film; when the rapid detection structure is a fluorescent immunoassay structure, the detection reagent strip is prepared by using a fluorescent microsphere or fluorescein as an indicator through a fluorescent immunoassay method, and a sample pad, a fluorescent marker binding pad coated with a fluorescent marker, a nitrocellulose membrane pad coated with a non-marked capture reagent and a water absorption pad are sequentially adhered on a PVC negative film.
The semi-quantitative detection specific operation comprises the following steps: 1) Taking out the chromatographic detection structure, the saliva sample moving structure and the saliva sampling structure, and exposing an opening of the saliva sampling structure; a handheld saliva sampling structure that collects saliva into the sampling container structure; taking out the saliva sample transferring structure, sucking a proper amount of saliva sample, and dripping the saliva sample into a sample adding hole of the chromatographic detection structure; the saliva sample passes through the sample pad and forwards flows through the marker binding pad, the nitrocellulose membrane and the water absorption pad; and reading the detection result from the observation window to finish detection. 2) Placing a sampling head of the saliva sampling structure into an oral cavity, and naturally absorbing saliva samples until the sampling head is completely infiltrated by saliva; 3) The sampled saliva sampling structure sampling head is inserted into a sample adding connection structure of the chromatographic detection structure 2, the sampled saliva sample is transferred to a sample pad, and forwards flows through a marker binding pad, a nitrocellulose membrane and a water absorption pad; 4) And reading a detection result from the observation window, comparing the color depth of the detection line with the semi-quantitative color comparison card, and reading a semi-quantitative range value to finish detection.
The specific quantitative detection operation comprises the following steps: 1) Taking out the chromatographic detection structure, the saliva sample moving structure and the saliva sampling structure, and exposing an opening of the saliva sampling structure; a handheld saliva sampling structure that collects saliva into the sampling container structure; taking out the saliva sample transferring structure, sucking a proper amount of saliva sample, and dripping the saliva sample into a sample adding hole of the chromatographic detection structure; the saliva sample passes through the sample pad and forwards flows through the marker binding pad, the nitrocellulose membrane and the water absorption pad; and reading the detection result from the observation window to finish detection. 2) Placing a sampling head of the saliva sampling structure into an oral cavity, and naturally absorbing saliva samples until the sampling head is completely infiltrated by saliva; 3) The sampled saliva sampling structure sampling head is inserted into a sample adding connection structure of the chromatographic detection structure 2, the sampled saliva sample is transferred to a sample pad, and forwards flows through a marker binding pad, a nitrocellulose membrane and a water absorption pad; 4) And (3) placing the chromatographic detection structure in a quantitative detector, reading the detection result, and quantitatively calculating the measurement value to finish detection.
Experimental study of the utility model: the following experiments illustrate the detection method and the effect of the present utility model, but are not limiting of the present utility model. The experimental methods used in the following experiments are conventional methods unless otherwise specified. The materials, reagents and the like used, unless otherwise specified, are all commercially available.
Experiment one: immune colloidal gold method saliva insulin rapid detection experiment:
1. preparing a detection reagent strip:
the method comprises the steps of preparing a detection reagent strip by adopting a double-antibody sandwich method by adopting a conventional immune colloidal gold detection technology, preparing a detection kit by adopting the rapid detection structure of the utility model, and carrying out an insulin detection experiment, wherein an antibody of a colloidal gold marked indicator of a detection line T of the detection reagent strip is a first anti-insulin monoclonal antibody of 10ug/ml, the particle size of colloidal gold particles of a colloidal gold solution is about 50nm, and the marked colloidal gold solution is coated on a glass cellulose membrane colloidal gold binding pad; the capture antibody of the detection line T of the detection reagent strip is a matched non-labeled second anti-insulin monoclonal antibody, the coating concentration is 1.0mg/ml, and the capture antibody is coated on a nitrocellulose membrane pad; the capture antibody of the quality control line C of the detection reagent strip is a goat anti-mouse IgG polyclonal antibody of 1.0mg/ml, and the capture antibody is coated on a nitrocellulose membrane pad and used for capturing a first anti-insulin monoclonal antibody which is not specifically captured and marked by colloidal gold. The two ends of the nitrocellulose membrane pad printing membrane are respectively stuck with a water absorption pad and a colloidal gold mark bonding pad, and one side of the colloidal gold mark bonding pad is stuck with a sample pad. Placing the stuck detection sheet on a slitter, and cutting into detection reagent strips with the thickness of 3.5 mm.
2. The rapid detection structure of the utility model is prepared by the following steps:
the upper cover and the base of the detection shell of the chromatography detection structure are designed by Solidworks, a 3D printing sample is used, a sample adding dropper with the commercial capacity of 100ul is adopted as a saliva sample moving structure, a funnel with the commercial upper opening outer diameter of 30mm and a small-sized storage tube for experiments are adopted as a saliva sampling structure, and a rapid detection structure sample is prepared for experimental detection. Red color cards with different color depths are printed.
3. Experimental method and results:
during the experiment, the prepared detection reagent strip and the detection structure shell are assembled into an integrated chromatography detection structure, the assembled chromatography detection structure is placed into an aluminum foil sealing bag with a drying agent, and the aluminum foil sealing bag is sealed on a sealing machine and labeled. Recombinant insulin glargine injection (100 IU/ml) was prepared by using 10mM phosphate buffer solution (1, 5, 10, 15, 20, 25, 30 uIU/ml). Taking 80ul of prepared recombinant insulin glargine solution, directly dripping insulin solutions with different concentrations to a chromatographic detection structure sample adding window, standing for 15 minutes, checking the color depth of a detection line through an observation window, photographing, and printing 7 purple red color cards with different color depths to obtain a semi-quantitative color card.
The saliva sampling structure of the prepared rapid detection structure sample is used for respectively collecting 80ul saliva samples of 10 healthy donors with a fasting state and 2 hours after meal, the saliva samples are respectively and directly loaded into a sample adding window of the chromatography detection structure, the sample is stood for 15 minutes, the color depth of a detection line is checked through an observation window, the sample is colorimetric with a semi-quantitative colorimetric card, the concentration range of a colorimetric result is judged, the fasting state is about 1-12uU/ml, the postprandial time is about 10-30uU/ml, and the sample meets the detection range of normal people.
Experiment II: color latex microsphere immunochromatography insulin rapid detection experiment:
1. preparing a detection reagent strip:
preparing a detection reagent strip by adopting a double-antibody sandwich method by adopting a conventional color latex microsphere immunochromatography technology, preparing a detection kit by adopting the rapid detection structure of the utility model for insulin detection experiments, wherein the color latex microsphere adopts a biological 300nm red microsphere, a latex microsphere mark of a detection line T of the detection reagent strip indicates that an antibody is a first anti-insulin monoclonal antibody of 50ug/ml, and a marked latex microsphere mark liquid is coated on a glass cellulose membrane bonding pad; the capture antibody of the detection line T of the detection reagent strip is a paired non-labeled second anti-insulin monoclonal antibody, and the coating concentration is 1.0mg/ml, and the coated cellulose nitrate membrane is coated on a nitrocellulose membrane pad; the capture antibody of the quality control line C of the detection reagent strip is a goat anti-mouse IgG polyclonal antibody of 1.0mg/ml, and the goat anti-mouse IgG polyclonal antibody is coated on a nitrocellulose membrane pad and used for capturing the color latex microsphere marked anti-insulin monoclonal antibody which is not specifically captured. And respectively adhering a water absorption pad and a latex microsphere marking combination pad at two ends of the nitrocellulose membrane pad printing membrane, and adhering a sample pad at the other side of the latex microsphere marking combination pad. Placing the stuck detection sheet on a slitter, and cutting into detection reagent strips with the thickness of 3.5 mm.
2. The rapid detection structure of the utility model is prepared by the following steps:
prepared in the same experiment one and two.
3. Experimental method and results:
during the experiment, the prepared detection reagent strip and the rapid detection structure shell are assembled into an integrated chromatography detection structure, the assembled detection chromatography detection structure is placed into an aluminum foil sealing bag with a drying agent, and the aluminum foil sealing bag is sealed on a sealing machine and labeled. Recombinant insulin glargine injection (100 IU/ml) was prepared by using 10mM phosphate buffer solution (1, 5, 10, 15, 20, 25, 30 uIU/ml). Taking 80ul of prepared recombinant insulin glargine solution, directly dripping insulin solutions with different concentrations to a chromatographic detection structure sample adding window, standing for 15 minutes, checking the color depth of a detection line through an observation window, photographing, and printing 7 red color cards with different color depths to obtain a semi-quantitative color card.
The saliva sampling structure of the prepared rapid detection structure sample is used for respectively collecting 80ul saliva samples of 10 healthy donors in 2 hours on an empty stomach and after meal, the saliva samples are respectively and directly loaded into a sample adding window of the chromatographic detection structure, the sample is stood for 15 minutes, the color depth of a detection line is checked through an observation window, the sample is colorimetric with a semi-quantitative colorimetric card, the concentration range of a colorimetric result is judged, the empty stomach is about 1-15uU/ml, the after meal is about 5-30uU/ml, and the sample meets the detection range of normal people.
Experiment III: immunofluorescence method insulin rapid detection experiment:
1. preparing a detection reagent strip:
preparing a detection reagent strip by adopting a double-antibody sandwich method by adopting a conventional immunofluorescence detection technology, preparing a detection reagent kit by adopting the rapid detection structure of the utility model, and carrying out an insulin detection experiment, wherein a fluorescent microsphere marked antibody of the detection reagent strip adopts a first anti-insulin monoclonal antibody with the particle size of 30ug/ml, fluorescent microspheres adopt fluorescent microspheres with the particle size of 300nm of the biological company, and fluorescent microsphere liquid of the marked antibody is coated on a glass cellulose membrane marker binding pad; the capture antibody of the detection reagent strip is 1.0mg/ml of paired non-labeled second anti-insulin monoclonal antibody, and the detection reagent strip is coated on a nitrocellulose membrane; the capture antibody of the quality control line C of the detection reagent strip is a goat anti-mouse IgG polyclonal antibody of 1.0mg/ml, and the goat anti-mouse IgG polyclonal antibody is coated on a nitrocellulose membrane and used for capturing fluorescent microsphere labeled first anti-insulin monoclonal antibodies which are not specifically captured. The two ends of the nitrocellulose membrane are respectively stuck with a water absorption paper membrane pad and a fluorescent microsphere marking combination membrane pad, and the other side of the combination membrane pad is stuck with a sample pad. Placing the stuck detection sheet on a strip cutting machine, and cutting into 3.5mm test strips.
2. The rapid detection structure of the utility model is prepared by the following steps:
prepared in the same experiment one and two.
3. Fluorescence detector: a commercially available Bos AFS-100 fluorescence detector was used.
4. Experimental method and results:
during experiments, the prepared detection reagent strip and the rapid detection structure shell are assembled into an integrated chromatography detection kit, the assembled chromatography detection kit is placed into an aluminum-amber sealing bag with a drying agent, and the sealing machine is used for sealing and labeling. A standard curve of recombinant insulin glargine concentration and fluorescence reaction of Changxiu insulin glargine is established by using the prepared detection kit and a fluorescence quantitative analyzer by preparing Changxiu insulin glargine injection (100 IU/ml) of 1, 5, 10, 15, 20, 25 and 30 uIU/ml with 10mM phosphate buffer solution. The prepared saliva sampling structure is used for respectively collecting 80ul of saliva samples of 10 healthy donors with 2 hours of empty stomach and postprandial, the saliva samples are respectively and directly loaded into a sample adding window of a prepared detection kit, the sample is stood for 15 minutes, a fluorescent quantitative analyzer is arranged for detecting fluorescent values, the insulin concentration of the saliva samples is calculated through a standard curve, the empty stomach is 9.55+/-2.31 uIU/ml, and the postprandial time is 23.13+/-5.67 uIU/ml, so that the sample meets the detection range of normal people.
Claims (7)
1. A rapid detection structure of saliva insulin level, characterized in that:
1) The rapid detection structure is a combined detection structure of a saliva sampling structure, a saliva sample moving structure and a chromatography detection structure;
2) The chromatographic detection structure comprises a detection reagent strip, a detection shell upper cover and a detection shell base, a sample adding hole and an observation window which are arranged on the detection shell upper cover, and a detection reagent strip bracket arranged on the detection shell base, wherein the detection shell upper cover and the detection shell base are used for placing the detection reagent strip;
3) The detection reagent strip comprises a sample pad, a marker binding pad, a nitrocellulose membrane and a water absorption pad, wherein the marker binding pad is coated with a first anti-insulin antibody marked by an indicator, and the nitrocellulose membrane is coated with a second non-marked anti-insulin antibody;
4) The saliva sampling structure is a container-like structure with an upward opening and comprises a cup shape or a tubular shape;
5) The saliva sample transferring structure is a liquid transferring straw structure and comprises a liquid transferring straw with a sealed top end or a liquid transferring straw with an opened top end.
2. The rapid test structure of claim 1, wherein the saliva sampling structure is a cup-shaped structure provided with a handle.
3. The rapid test structure of claim 1, wherein the saliva sampling structure is a folded open-ended container-like structure, the bottom is sealed and pressure on both sides opens the opening into a container structure.
4. The rapid test structure of claim 1, wherein the saliva sampling structure is a removable structure provided with a funnel-like sampling structure and a container-like collection structure.
5. The rapid assay structure of claim 1, wherein the assay reagent strip is at least one of a colloidal gold immunoassay reagent strip, a fluorescent immunoassay reagent strip, a color latex microsphere immunoassay reagent strip, and the indicator is at least one of colloidal gold particles, color latex microspheres, and fluorescent substances.
6. The rapid test structure of claim 1, wherein the rapid test structure is configured with a semi-quantitative color chart of consistent color with the indicator, the color chart having 3 or more color depth strips printed thereon.
7. The rapid detection structure of claim 1, wherein the rapid detection structure is configured with a portable quantitative detector comprising at least one of a colorimetric quantitative analyzer and a fluorescent quantitative analyzer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202321130177.4U CN219810955U (en) | 2023-05-11 | 2023-05-11 | Saliva insulin level's short-term test structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202321130177.4U CN219810955U (en) | 2023-05-11 | 2023-05-11 | Saliva insulin level's short-term test structure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN219810955U true CN219810955U (en) | 2023-10-10 |
Family
ID=88208945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202321130177.4U Active CN219810955U (en) | 2023-05-11 | 2023-05-11 | Saliva insulin level's short-term test structure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN219810955U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222543A1 (en) * | 2023-04-23 | 2024-10-31 | 闫丽霞 | Structure for detecting level of insulin in saliva and use thereof |
-
2023
- 2023-05-11 CN CN202321130177.4U patent/CN219810955U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222543A1 (en) * | 2023-04-23 | 2024-10-31 | 闫丽霞 | Structure for detecting level of insulin in saliva and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01229969A (en) | Improved immunological analysis of membrane support type | |
| CN113740527A (en) | Sampling and detection integrated rapid detection structure and application thereof | |
| EP2930516A1 (en) | Pregnancy testing | |
| CN102207507A (en) | Semi-quantitative detecting test paper of cardiac troponin and preparation method thereof | |
| CN113848323A (en) | Column pushing type sampling detection integrated rapid detection structure and application thereof | |
| CN219810955U (en) | Saliva insulin level's short-term test structure | |
| CN114942328A (en) | Rapid detection structure for blood insulin level and application thereof | |
| CN216117640U (en) | Sampling and detection integrated rapid detection structure | |
| CN116519957A (en) | Rapid detection structure for saliva insulin level and application thereof | |
| CN102636651A (en) | Method, system and chip test paper for parallel detection on various cardiac markers | |
| CN114527282A (en) | Detection technology for saliva and nasal cavity double-sample integrated sample adding and application thereof | |
| CN216209190U (en) | Rapid detection structure for liquid phase sample sampling and detection | |
| CN219810954U (en) | Membrane chromatography detection structure of saliva insulin level | |
| WO2023147713A1 (en) | Combined detection structure for dual sampling and integrated detection and use thereof | |
| CN217688978U (en) | Quick detection structure of blood insulin level | |
| CN201087838Y (en) | Myocardium calcium protein I color particle diagnosis test paper | |
| CN116449028A (en) | Membrane chromatography detection structure for saliva insulin level and application thereof | |
| CN219846638U (en) | Sampling and detecting integrated structure for saliva insulin detection | |
| CN201096787Y (en) | C-reaction albumen color grain diagnosis testing paper | |
| CN116439754A (en) | Sampling and detecting integrated structure for saliva insulin detection | |
| CN216209194U (en) | Quick detection structure of integration is detected in sampling of post pushing-type | |
| WO2025044102A1 (en) | Test strip for detecting human chorionic gonadotropin in saliva and preparation method therefor | |
| CN219434845U (en) | Myocardial marker rapid detection kit for combined detection | |
| CN207248887U (en) | Canine parvovirus time-resolved fluoroimmunoassay chromatographs detection kit | |
| CN113899897A (en) | A rapid detection structure for liquid sample sampling and detection and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |